Clinical and preclinical

Ischemic stroke

Stroke is a cerebrovascular disease with high rates of fatality. Tissue Plasminogen Activitor, the only approved treatment is available for 5-10% of patients only.

MEDICAL NEED

  • 87 % of all strokes are ischemic stroke
  • 2nd most common cause of death worldwide

RATIONALE FOR CD34+

  • CD34+ in patients with acute ischemic stroke, showed improvement in clinical, functional scores and reduction in lesion volume1

Refractory Angina

Stroke is a cerebrovascular disease with high rates of fatality. Tissue Plasminogen Activitor, the only approved treatment is available for 5-10% of patients only.

Refractory angina is caused by diffuse vascular disease. 

It cannot be controlled by a combination of maximal medical therapy, bypass surgery, and percutaneous intervention

  • Chronic coronary artery disease
  • Prevalence increasing globally
  • Incomplete revascularization is a major factor

 angiogenic property of CD34+ cells

 

 

MEDICAL NEED

Refractory angina (RFA) is chronic chest pain due to furring up of the blood supply to the heart that causes unbearable symptoms and poor quality of life despite current medical treatment, angioplasty, or bypass surgery. New cases are estimated at 75 000 in the US (1), 30,000- 50 000 in Europe (2) and just under 20,000 in the UK(3). These patients pose significant healthcare costs as presentations are treated as suspected heart attacks with overnight admissions and frequent hospitalisations. Despite the availability of different treatments for coronary artery disease, RFA patients have limited treatment options as their disease cannot be treated with conventional treatment methods.

 

RATIONALE FOR CD34+

  • ProtheraCytes® contains endothelial and cardiac progenitor cells that can regenerate and revascularize damaged cardiac and endothelial tissue

CellProthera is most enthusiastic and strive to find solutions to medical unmet needs and provide patients with means that would improve their quality of life and global health.